The Breakthrough Drug Whose Full Promise Remains Unrealized The Breakthrough Drug Whose Full Promise Remains Unrealized
With its approval in 2013, sofosbuvir revolutionized treatment for hepatitis C, but the goal of eliminating this disease is still decades away.Medscape Gastroenterology (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - January 22, 2024 Category: Gastroenterology Tags: Gastroenterology Commentary Source Type: news

The Hepatitis C Crisis Epitomizes The Problems With U.S. Healthcare
There has been a cure for Hepatitis C since 2014, yet nearly four million Americans are living with the viral infection, according to American Liver Foundation. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 16, 2024 Category: Pharmaceuticals Authors: Omer Awan, Contributor Tags: Healthcare /healthcare Innovation /innovation standard Source Type: news

What The Hepatitis C Crisis Says About The U.S. Healthcare System
There has been a cure for Hepatitis C since 2014, yet nearly 4 million Americans are living with the viral infection, according to American Liver Foundation. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 16, 2024 Category: Pharmaceuticals Authors: Omer Awan, Contributor Tags: Healthcare /healthcare Innovation /innovation standard Source Type: news

Patient adherence to ultrasound liver cancer surveillance recs is low
Patient adherence to ultrasound hepatocellular carcinoma (HCC) surveillance imaging recommendations has been suboptimal, according to research published January 12 in Radiology: Imaging Cancer.Ultrasound is considered a cost-effective surveillance method in the management of HCC, a common type of liver cancer associated with long-term liver damage and scarring of the liver and chronic infections such as hepatitis B and hepatitis C, a research team from the University of California, San Francisco (UCSF) noted. But whether patients comply with surveillance recommendations prompted by the ultrasound LI-RADS metric isn't cle...
Source: AuntMinnie.com Headlines - January 16, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news

LI-RADS shows low NPV in per-patient liver tumor assessment
Per-patient grouping for liver tumor status based on LI-RADS and treatment response shows low negative predictive value (NPV) in detecting residual or untreated tumors, according to research published December 19 in Radiology.  A team led by Omar Hassan, MD, from the University of California, San Francisco studied hepatocellular carcinoma (HCC) patients who underwent local-regional therapy followed by liver transplant. The team found that per-patient stratification of tumor status at either pretransplant CT or MRI based on the LI-RADS version 2018 treatment response algorithm showed low NPV in this area. “The relativel...
Source: AuntMinnie.com Headlines - December 20, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: MRI Abdominal Imaging Source Type: news

Guideline Updated for Managing Hepatitis C in Chronic Kidney Disease
TUESDAY, Dec. 12, 2023 -- The Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline on prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease has been updated, according to a report... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 12, 2023 Category: Pharmaceuticals Source Type: news

Infected Blood Scandal: PM risks ending on 'wrong side of history'
Campaigners say the government works "at a snails pace" to compensate victims infected with HIV or hepatitis C. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - December 5, 2023 Category: Consumer Health News Source Type: news

Two-Week Prophylaxis May Prevent Hep C After Kidney Transplant
(MedPage Today) -- Short-term prophylaxis with direct-acting antivirals was fully effective at protecting kidney transplant recipients when their donors had hepatitis C, a proof-of-concept study showed. In the small, uncontrolled trial, a 2-week... (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - December 1, 2023 Category: Urology & Nephrology Source Type: news

Implicit bias from providers inhibits hepatitis C treatment
A new study reveals significant insights into the challenges that can occur in hepatitis C virus elimination efforts in people with HIV. (Source: Yale Science and Health News)
Source: Yale Science and Health News - November 29, 2023 Category: Universities & Medical Training Source Type: news

Two-Week DAA Prophylaxis Prevents Hep C After Kidney Transplant
TUESDAY, Nov. 28, 2023 -- Two-week direct-acting antiviral (DAA) prophylaxis prevents hepatitis C virus (HCV) infection in individuals without HCV viremia who received kidney transplant (KT) from donors with HCV viremia (HCV D+/R−), according... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 28, 2023 Category: Pharmaceuticals Source Type: news

Egypt Wiped Out Hepatitis C. Now It Is Trying to Help the Rest of Africa.
Effective drugs that have made the disease curable have yet to reach most of the region. (Source: NYT Health)
Source: NYT Health - November 28, 2023 Category: Consumer Health News Authors: Stephanie Nolen and Natalija Gormalova Tags: Hepatitis Medicine and Health International Relations Developing Countries World Health Organization Africa Egypt Ghana your-feed-healthcare your-feed-science Source Type: news

Roche expands hepatitis diagnostics portfolio to help clinicians diagnose and monitor patients with acute or chronic hepatitis B infection
Elecsys ® HBeAg quant is an immunoassay that can be used as an early marker of acute hepatitis B infection, as well as an indicator of chronic active hepatitis in combination with other laboratory results and clinical information.The single test will inform clinicians if treatment is required and regimens are working in conjunction with other diagnostic assays.Almost 300 million people globally have chronic hepatitis B, causing a significant burden to health systems as it puts patients at high risk of death from cirrhosis and liver cancer.1Basel, 27 November 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the la...
Source: Roche Media News - November 27, 2023 Category: Pharmaceuticals Source Type: news

Hep C: More than 70% of Bristolians 'know nothing' of virus
Keith Hathaway, from Bristol, is promoting awareness of blood-borne viruses such as Hepatitis C. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - November 23, 2023 Category: Consumer Health News Source Type: news

Direct-Acting Antivirals Still Underused in Hep C-Related Liver Cancer
TUESDAY, Nov. 21, 2023 -- Direct-acting antiviral agents (DAAs) remain underutilized in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC), according to a study presented at The Liver Meeting, the annual meeting of the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 21, 2023 Category: Pharmaceuticals Source Type: news

With rise of GLP-1 drugs, Peninsula biopharma targets another approach to diabetes and obesity
The founder and CEO of the startup worked on groundbreaking hepatitis C drugs as well as less-successful "fatty liver" drugs at Gilead Sciences. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 21, 2023 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news